Cyclacel Pharmaceuticals, Inc. (CYCC)
USD 0.34
(-7.13%)
USD 0.34
(-7.13%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 420 Thousand | - | - | - | - | 150 Thousand |
| Cost of Revenue | 31 Thousand | 32 Thousand | 43 Thousand | 20 Thousand | 20 Thousand | 4.32 Million |
| Gross Profit | 389 Thousand | -32 Thousand | -43 Thousand | -20 Thousand | -20 Thousand | -4.17 Million |
| Operating Expenses | 25.87 Million | 27.65 Million | 22.93 Million | 10.63 Million | 9.68 Million | 9.69 Million |
| Selling, General and Administrative Expenses | 6.71 Million | 7.38 Million | 7.46 Million | 5.87 Million | 5.02 Million | 5.37 Million |
| Research and Development Expenses | 19.15 Million | 20.27 Million | 15.47 Million | 4.75 Million | 4.65 Million | 4.32 Million |
| Other Expenses | - | 1.29 Million | 144 Thousand | 891 Thousand | 231 Thousand | 682 Thousand |
| Cost and Expenses | 25.87 Million | 27.65 Million | 22.93 Million | 10.63 Million | 9.68 Million | 9.69 Million |
| Operating Income | -25.45 Million | -27.65 Million | -22.93 Million | -10.63 Million | -9.68 Million | -9.54 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | -2.99 Million | -4.71 Million | -3.84 Million | -1.23 Million | -1.29 Million | -1.33 Million |
| Earnings before Tax | -25.55 Million | -25.91 Million | -22.73 Million | -9.68 Million | -9.12 Million | -8.62 Million |
| Net Income | -22.55 Million | -21.19 Million | -18.88 Million | -8.44 Million | -7.82 Million | -7.28 Million |
| Earnings Per Share Basic | -26.75 | -32.23 | -31.74 | -34.86 | -143.88 | -12.05 |
| Earnings Per Share Diluted | -26.75 | -32.23 | -31.74 | -34.86 | -143.88 | -12.05 |
| Weighted Average Shares Outstanding | 850.81 Thousand | 657.61 Thousand | 595.07 Thousand | 242.22 Thousand | 54.4 Thousand | 604.7 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 850.81 Thousand | 657.61 Thousand | 595.07 Thousand | 242.22 Thousand | 54.4 Thousand | 604.7 Thousand |
| Gross Margin | 0.93 | - | - | - | - | -27.85 |
| EBIT Margin | -60.53 | - | - | - | - | -63.05 |
| Profit Margin | -53.70 | - | - | - | - | -48.59 |
| EBITDA | -25.42 Million | -27.62 Million | -22.69 Million | -10.61 Million | -9.66 Million | -9.51 Million |
| Earnings Before Tax Margin | -60.60 | - | - | - | - | -63.65 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 4000.00 | 29 Thousand | 31 Thousand | 420 Thousand | 16 Thousand | 373 Thousand |
| Cost of Revenue | 2000.00 | 2000.00 | 8000.00 | 31 Thousand | 7000.00 | 372.62 Thousand |
| Gross Profit | 2000.00 | 27 Thousand | 23 Thousand | 389 Thousand | 9000.00 | 373.00 |
| Operating Expenses | 4.43 Million | 7.3 Million | 5.78 Million | 30.68 Million | 6.86 Million | 6.3 Million |
| Selling, General and Administrative Expenses | 1.62 Million | 1.58 Million | 1.87 Million | - | 1.62 Million | 1.57 Million |
| Research and Development Expenses | 2.81 Million | 5.72 Million | 3.91 Million | - | 5.23 Million | 4.72 Million |
| Other Expenses | - | 52 Thousand | -52 Thousand | 50 Thousand | -8000.00 | -106 Thousand |
| Cost and Expenses | 4.43 Million | 7.3 Million | 5.79 Million | 30.71 Million | 6.86 Million | 6.3 Million |
| Operating Income | -4.43 Million | -7.28 Million | -5.76 Million | -30.29 Million | -6.84 Million | -5.92 Million |
| Interest Expense | 28 Thousand | - | 108 Thousand | - | - | - |
| Income Tax Expense | -1.2 Million | -4.27 Million | -822 Thousand | -7.84 Million | -602 Thousand | -586 Thousand |
| Earnings before Tax | -4.45 Million | -7.22 Million | -6.09 Million | -30.39 Million | -6.69 Million | -6.03 Million |
| Net Income | -3.25 Million | -2.94 Million | -5.27 Million | -22.55 Million | -6.09 Million | -5.44 Million |
| Earnings Per Share Basic | -1.80 | -2.27 | -6.17 | - | -7.23 | -6.51 |
| Earnings Per Share Diluted | -1.80 | -2.27 | -6.17 | - | -7.23 | -6.51 |
| Weighted Average Shares Outstanding | 1.8 Million | 1.29 Million | 854.03 Thousand | 850.81 Thousand | 842.85 Thousand | 836.78 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 1.8 Million | 1.29 Million | 854.03 Thousand | 850.81 Thousand | 842.85 Thousand | 836.78 Thousand |
| Gross Margin | 0.50 | 0.93 | 0.74 | 0.93 | 0.56 | 0.00 |
| EBIT Margin | -1108.00 | -250.97 | -185.55 | - | -434.31 | -15.67 |
| Profit Margin | -814.25 | -101.59 | -170.03 | -53.70 | -381.06 | -14.61 |
| EBITDA | -4.43 Million | -7.27 Million | -5.75 Million | - | -6.94 Million | -5.84 Million |
| Earnings Before Tax Margin | -1108.50 | -251.03 | -185.81 | -72.14 | -427.81 | -15.90 |
BLUMY
COMAN
4003
601336
6826
SY1